Clinical trials of single-agent trastuzumab (Herceptin).

@article{Baselga2000ClinicalTO,
  title={Clinical trials of single-agent trastuzumab (Herceptin).},
  author={Jos{\'e} Baselga},
  journal={Seminars in oncology},
  year={2000},
  volume={27 5 Suppl 9},
  pages={20-6}
}
The HER2 gene (also known as neu and as c-erb-B2) encodes a 185-kd transmembrane glycoprotein receptor with intrinsic tyrosine kinase activity. HER2 is overexpressed in 25% to 30% of human breast cancers, plays a role in the pathogenesis of breast cancer, and predicts for a worse prognosis in patients with metastatic disease. Trastuzumab (Herceptin; Genentech, Inc, So. San Francisco, CA), a humanized monoclonal antibody that targets the HER2 oncogene receptor, was shown to be active in… CONTINUE READING
14 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…